Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.128 -0.212 (-4.87%)
Streaming Delayed Price Updated: 11:17 AM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA
When most people think of lung cancer, they often picture a smoker. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study
The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with... 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
From Lantern Pharma Inc.
Via Business Wire
Recap: Lantern Pharma Q1 Earnings
Lantern Pharma (NASDAQ:LTRN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lantern Pharma missed estimated... 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Lantern Pharma Earnings Preview
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Lantern... 
Via Benzinga
Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial... 
From RedChip
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma: Q4 Earnings Insights
Lantern Pharma (NASDAQ:LTRN) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Outlook For Lantern Pharma
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Benzinga Announces This Week's All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, presented by RedChip, set to air Friday, January 28 at 9:15 am ET. The Lineup 9:15 am:... 
Via Benzinga
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce... 
From RedChip
Via AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 15.0% to $6.3 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer
The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor... 
Via Benzinga
Earnings Scheduled For November 1, 2021
Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter. • Kiniksa Pharmaceuticals (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of their outstanding shares is at $417.9 million.... 
Via Benzinga
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to... 
From Lantern Pharma
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication
The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas. The news follows the... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.